Zymeworks Inc. (ZYME)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Kenneth H. Galbraith C.A. | Chairman of the Board, CEO & President | 1.16M | -- | 1963 |
| Dr. Paul A. Moore Ph.D. | Chief Scientific Officer | 757.5k | -- | 1968 |
| Mr. Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | -- | -- | 1970 |
| Ms. Shrinal Inamdar | Director of Investor Relations | -- | -- | -- |
| Mr. Daniel Dex J.D., Ph.D. | Senior VP, Corporate Secretary & General Counsel | -- | -- | -- |
| Diana Papove | Senior Manager of Corporate Communications | -- | -- | -- |
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development | -- | -- | -- |
| Ms. Laura O'Connor | Vice President of Human Resources & DEI | -- | -- | -- |
| Mr. John Fann Ph.D. | Senior Vice President of Process Sciences | -- | -- | -- |
Zymeworks Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 280
Description
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Corporate Governance
Upcoming Events
May 8, 2025 at 8:00 PM UTC
Zymeworks Inc. Earnings Date